LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection. A monoclonal for SARS-CoV-2 Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days and a clearance of 0.22 ml hour −1 kg −1 , consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study day 6 after viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment.
【초록키워드】 COVID-19, Treatment, coronavirus disease, neutralizing antibody, SARS-CoV-2, Respiratory distress syndrome, Coronavirus disease 2019, vaccination, Hospitalized, acute respiratory distress syndrome, Neutralizing antibodies, antibody, Therapeutics, monoclonal antibody, Infection, B cells, severe acute respiratory syndrome coronavirus-2, in vitro, severe acute respiratory syndrome Coronavirus, monoclonal antibodies, angiotensin-converting enzyme 2, bamlanivimab, Population, Spike protein, airway, Antigen, Severe acute respiratory syndrome, Neutralizing activity, Antigen-specific B cells, Receptor-binding domain, viral replication, therapeutic, therapeutic agent, in vivo, Spectrum, mAbs, Anti-spike, convalescent patient, LY-CoV555, monoclonal, binding, SARS-CoV-2 spike, mAb, rhesus macaque, Angiotensin-converting enzyme, acute respiratory distress, Coronavirus-2, pharmacokinetic, Interaction, angiotensin, Lower respiratory tract, airways, therapeutic option, respiratory distress, prophylactic dose, prophylactic doses, Support, Clinical use, acute respiratory syndrome, severe acute respiratory distress syndrome, acute respiratory syndrome coronavirus, These data, individual, indications, syndrome, upper and lower respiratory tracts, upper and lower respiratory tract, clinical testing, rhesus, clearance, prophylactic treatment, offer, public health threat, high-affinity binding, widespread, neutralize, PROTECT, Jones, tested, collected, evaluated, conducted, reduced, characterized, functional, less, demonstrated, the receptor-binding domain, prevented, antigen-specific B cell, infected with SARS-CoV-2, Jone, patients with COVID-19, 【제목키워드】 neutralizing antibody, SARS-COV-2 infection, PROTECT,